Educational Sessions
Saturday, April 22, 2017
Saturday, April 22, 2017
Dental Trends Driving a Paradigm Shift
Efficacy and Safety of Intranasal 3%
Tetracaine plus 0.05% Oxymetazoline
Choice of sessions at 8:30 a.m. – 9:30 a.m.;
11:30 a.m. – 12:30 p.m. or 2:15 p.m. – 3:15 p.m.
Presented by Dr. David M. Preble
No continuing education credits are offered. Sessions
are free of charge for PDA/ADA member dentists but
pre-registration is required and meals are not included.
Each interactive session provides attendees with the
opportunity to examine economic trends and position
your practice to thrive.
- What are the market forces driving change?
- What are the misconceptions about contracting with
third-party payers?
- What resources are available to help you manage?
Attend and find out.
About the Speaker
David M. Preble, DDS, JD, CAE
Dr. Preble is the vice president of the
ADA’s Practice Institute. He practiced
general dentistry in both private
practice and public health settings for more than 20 years
before joining the ADA. He graduated from Marquette
University in 1976, Georgetown University Dental School
in 1980 and St. Thomas University School of Law in 1994.
Dave has earned a certificate in non-profit management
from the Kellogg School of Management, is a Certified
Dental Consultant and a Certified Association Executive.
Dr. Preble has no relevant financial relationships to disclose.
Choice of sessions at 10:00 a.m. – 11:00 a.m.; 12:45 p.m.
– 1:45 p.m. or 2:15 p.m. – 3:15 p.m.
Presented by Dr. Elliot V. Hersh
Each course is 1 hour of continuing education credit
appropriate for dentists and hygienists licensed to
administer local anesthesia. Meals are not included with
registration.
Local anesthetics and their associated vasoconstrictors
have had a long history of safety and efficacy in dental
practice. For many patients the most painful or only
painful part of routine dental procedures is the local
anesthetic injection itself. Intranasal 3% tetracaine plus
0.05% oxymetazoline (Kovanzaze®) received FDA approval
on June 29, 2016, to provide maxillary anesthesia for a
single restorative procedure from 2nd premolar to 2nd
premolar, and in all primary teeth in patients at least 88
pounds. This lecture will focus on the evidence-based
research performed by the speaker and others that
support the use of this novel formulation for routine
restorative dental procedures.
As a result of attending the lecture, participants should be
able to:
• Discuss the general pharmacology of tetracaine and
oxymetazoline.
• Identify the divisions of the maxillary nerve that this
formulation predictably anesthetizes.
• Describe common side effects experienced by patients
who have received intranasal tetracaine plus
oxymetazoline.
• Discuss additional post-marketing research that needs
to be performed with this drug.
22
N O V / D E C 2 0 1 6 | P E N N S Y LVA N I A D E N TA L J O U R N A L